Gennaro Musi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7580184/publications.pdf

Version: 2024-02-01

201674 276875 2,252 123 27 41 h-index citations g-index papers 126 126 126 2975 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	2.2	8
2	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	1.3	4
3	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU International, 2022, 129, 524-533.	2.5	4
4	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12
5	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. Clinical Genitourinary Cancer, 2022, 20, e339-e345.	1.9	6
6	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	1.6	0
7	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
8	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. Asian Journal of Andrology, 2022, 24, 579.	1.6	6
9	The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. Applied Sciences (Switzerland), 2022, 12, 2268.	2.5	4
10	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	2.6	14
11	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	O
12	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
13	Progress in prostate cancer prevention. European Journal of Cancer Prevention, 2022, 31, 554-557.	1.3	5
14	Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical Genitourinary Cancer, 2022, 20, e166-e172.	1.9	26
15	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq1 1 C).7843 2.4 rgBT	「/ Q verlock 10
16	Radiomics in prostate cancer: an up-to-date review. Therapeutic Advances in Urology, 2022, 14, 175628722211090.	2.0	62
17	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naÃ-ve patients: follow-up of a PRECISION trial-like retrospective cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 406-413.	3.9	9
18	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. BJU International, 2021, 127, 454-462.	2.5	3

#	Article	IF	CITATIONS
19	Synchronous Robot-Assisted Pulmonary and Urologic Resections for Cancer. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2021, 16, 101-103.	0.9	O
20	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. Surgical Oncology, 2021, 36, 131-137.	1.6	4
21	Double Loop Ureteral Stent Encrustation According to Indwelling Time: Results of a European Multicentric Study. Journal of Endourology, 2021, 35, 84-90.	2.1	14
22	Quality of life and psycho-emotional wellbeing in bladder cancer patients and their caregivers: a comparative analysis between urostomy versus ileal orthotopic neobladder. Ecancermedicalscience, 2021, 15, 1163.	1.1	8
23	Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer. BMC Cancer, 2021, 21, 51.	2.6	7
24	Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. Integrative Cancer Therapies, 2021, 20, 153473542110194.	2.0	5
25	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. Diagnostics, 2021, 11, 355.	2.6	12
26	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non–clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	3.1	10
27	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. European Urology Open Science, 2021, 27, 19-28.	0.4	11
28	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	1.6	2
29	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. Cancers, 2021, 13, 3278.	3.7	6
30	A risk-group classification model in patients with Abladder cancer Aunder neoadjuvant cisplatin-based combination chemotherapy. Future Oncology, 2021, 17, 3987-3994.	2.4	3
31	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Science OA, 2021, 7, FSO709.	1.9	40
32	Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the "Shell―Technique. Journal of Clinical Medicine, 2021, 10, 3601.	2.4	4
33	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. Frontiers in Oncology, 2021, 11, 732766.	2.8	2
34	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	2.5	23
35	Prostate Cancer Radiogenomicsâ€"From Imaging to Molecular Characterization. International Journal of Molecular Sciences, 2021, 22, 9971.	4.1	55
36	Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 736.e1-736.e7.	1.6	2

#	Article	IF	CITATIONS
37	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	1.4	20
38	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	2.2	3
39	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	3.7	21
40	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. Acta Biomedica, 2021, 92, e2021214.	0.3	0
41	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. Physica Medica, 2021, 92, 62-68.	0.7	4
42	Postoperative vacuum therapy following AMSa,, $^{\circ}$ LGX 700Â $^{\circ}$ inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. International Journal of Impotence Research, 2020, 32, 133-139.	1.8	6
43	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology, 2020, 38, 143-150.	2.2	49
44	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. Prostate Cancer and Prostatic Diseases, 2020, 23, 94-101.	3.9	4
45	Conditional survival of patients with stage l–III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World Journal of Urology, 2020, 38, 725-732.	2.2	10
46	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. Clinical Genitourinary Cancer, 2020, 18, e450-e456.	1.9	5
47	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. Clinical Genitourinary Cancer, 2020, 18, 117-128.e5.	1.9	6
48	Pathological findings at radical prostatectomy of biopsy na \tilde{A} -ve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e11-929.e19.	1.6	8
49	Radical penectomy, a compromise for life: results from the PECAD study. Translational Andrology and Urology, 2020, 9, 1306-1313.	1.4	9
50	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 567-574.	1.3	3
51	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. Scandinavian Journal of Urology, 2020, 54, 382-386.	1.0	2
52	Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. Therapeutic Advances in Urology, 2020, 12, 175628722091338.	2.0	3
53	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. Urologia Internationalis, 2020, 104, 510-522.	1.3	17
54	A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. Cancers, 2020, 12, 1513.	3.7	11

#	Article	IF	CITATIONS
55	Minimally invasive versus open radical cystectomy: long term oncologic outcomes compared. Translational Andrology and Urology, 2020, 9, 1006-1008.	1.4	2
56	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. BJU International, 2020, 126, 104-113.	2.5	21
57	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. Urology, 2020, 140, 91-97.	1.0	2
58	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 506-514.	1.6	4
59	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 600-607.	2.1	6
60	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	1.6	42
61	Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 nonâ€urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. International Journal of Urology, 2020, 27, 402-407.	1.0	1
62	Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences, 2020, 21, 1184.	4.1	45
63	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes and Control, 2020, 31, 263-272.	1.8	9
64	Insertion of a testicular prosthesis at the time of radical orchiectomy for testicular cancer is safe in patients who will subsequently undergo chemotherapy or radiotherapy. Andrologia, 2020, 52, e13613.	2.1	2
65	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World Journal of Urology, 2020, 38, 2819-2826.	2.2	10
66	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.4	61
67	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1
68	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 880-888.	1.3	5
69	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	2.2	77
70	Sexual function recovery after robotâ€assisted radical prostatectomy: Outcomes from an Italian referral centre and predicting nomogram. Andrologia, 2019, 51, e13385.	2.1	8
71	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 578.e11-578.e19.	1.6	9
72	Radioablation $+/\hat{a}$ hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer, 2019, 19, 903.	2.6	9

#	Article	IF	CITATIONS
73	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. International Journal of Radiation Oncology Biology Physics, 2019, 105, 735-744.	0.8	6
74	Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 262-272.	1.5	19
75	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e793-e801.	1.9	5
76	The impact of surgery for lower urinary tract symptoms/benign prostatic enlargement on both erectile and ejaculatory function: a systematic review. International Journal of Impotence Research, 2019, 31, 319-327.	1.8	11
77	Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients. European Radiology, 2019, 29, 5478-5487.	4.5	20
78	Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. Neoplasma, 2019, 66, 308-314.	1.6	6
79	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). British Journal of Radiology, 2019, 92, 20180494.	2.2	50
80	Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World Journal of Urology, 2019, 37, 1649-1657.	2.2	27
81	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?. Clinical Genitourinary Cancer, 2019, 17, 88-96.	1.9	22
82	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. Urologia Internationalis, 2019, 102, 43-50.	1.3	43
83	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. World Journal of Urology, 2019, 37, 1049-1059.	2.2	5
84	Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. Medical Oncology, 2019, 36, 9.	2.5	6
85	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. European Urology Focus, 2019, 5, 636-641.	3.1	19
86	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 31-37.	3.9	26
87	Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. Journal of Endourology, 2018, 32, 257-263.	2.1	51
88	Thulium–yttrium–aluminium–garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. World Journal of Urology, 2018, 36, 265-270.	2.2	15
89	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer. European Urology Oncology, 2018, 1, 403-410.	5.4	66
90	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. Journal of Cancer, 2018, 9, 4250-4254.	2.5	26

#	Article	IF	Citations
91	Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field. Annals of Surgical Oncology, 2018, 25, 3423-3424.	1.5	1
92	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	5 . 4	5
93	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	1.3	22
94	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	1.9	55
95	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Urologia Internationalis, 2018, 101, 56-64.	1.3	17
96	Splenodiaphragmatic colonic interposition and left hemidiaphragmatic elevation in a patient undergoing robot-assisted radical prostatectomy: a case report. Urology & Nephrology Open Access Journal, 2018, 6, .	0.1	0
97	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e661-e666.	1.9	47
98	Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did WeÂLearn?. Clinical Genitourinary Cancer, 2017, 15, e689-e696.	1.9	39
99	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clinical Genitourinary Cancer, 2017, 15, e623-e632.	1.9	71
100	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	1.0	42
101	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Translational Research, 2017, 184, 108-117.	5.0	56
102	Outcomes of robot-assisted simple enucleation of renal masses. Medicine (United States), 2017, 96, e6771.	1.0	4
103	Virtue male sling for postâ€prostatectomy stress incontinence: a prospective evaluation and midâ€ŧerm outcomes. BJU International, 2017, 119, 482-488.	2.5	34
104	Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. Therapeutic Advances in Urology, 2017, 9, 241-250.	2.0	7
105	Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. Ecancermedicalscience, 2017, 11, 786.	1.1	5
106	Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancermedicalscience, 2016, 10, 657.	1.1	4
107	Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. Medicine (United States), 2016, 95, e4519.	1.0	20
108	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	1.0	43

#	Article	IF	CITATIONS
109	Robot-assisted Radical Prostatectomy: Multiparametric MR Imaging–directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. Radiology, 2015, 274, 434-444.	7.3	48
110	Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 201.e1-201.e8.	1.6	54
111	Radiotherapy in Prostate Cancer Patients With Pelvic Lymphocele After Surgery: Clinical and Dosimetric Data of 30 Patients. Clinical Genitourinary Cancer, 2015, 13, e223-e228.	1.9	6
112	Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy. BJU International, 2014, 114, E3-E10.	2.5	7
113	A novel "intuitive―surgical technique for right robot-assisted retroperitoneal lymph node dissection for stage I testicular NSGCT. World Journal of Urology, 2013, 31, 435-439.	2.2	10
114	Intraoperative Frozen Pathology During Robot-Assisted Laparoscopic Radical Prostatectomy: Can ALEXISâ,,¢ Trocar Make it Easy and Fast?. Journal of Endourology, 2013, 27, 1213-1217.	2.1	10
115	Image Guided Hypofractionated Radiotherapy and Quality of Life for Localized Prostate Cancer: Prospective Longitudinal Study in 337 Patients. Journal of Urology, 2013, 189, 2099-2103.	0.4	19
116	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml. PLoS ONE, 2013, 8, e67687.	2.5	87
117	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 252.	1.1	4
118	Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt. Clinical Genitourinary Cancer, 2012, 10, 164-173.	1.9	45
119	Robotâ€assisted simple prostatectomy (RASP): does it make sense?. BJU International, 2012, 110, E972-9.	2.5	88
120	Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: Nonrandomized comparison with conventional fractionation. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 523-532.	1.6	28
121	Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients. International Journal of Radiation Oncology Biology Physics, 2008, 71, 784-794.	0.8	31
122	Sensitivity and Detection Rate of a 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report. European Urology, 2006, 49, 827-833.	1.9	35
123	Impact of the COVIDâ€19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan. BJUI Compass, 0, , .	1.3	3